{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:05:36Z","timestamp":1737435936796,"version":"3.33.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,20]]},"DOI":"10.7759\/cureus.77692","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T08:37:27Z","timestamp":1737362247000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of Relugolix for the Prevention of Impending Oliguria and Progressive Renal Failure in a Suspected Case of Prostate Carcinoma"],"prefix":"10.7759","author":[{"given":"Prem","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranjal","family":"Prem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Raut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamim","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.08.008","article-title":"Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?","volume":"75","author":"Oh WK","year":"2010","unstructured":"Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?. Urology. 2010, 75:642-7. 10.1016\/j.urology.2009.08.008","journal-title":"Urology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.45.1.391","article-title":"Gonadotropin-releasing hormone and its analogs","volume":"45","author":"Conn PM","year":"1994","unstructured":"Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994, 45:391-405. 10.1146\/annurev.med.45.1.391","journal-title":"Annu Rev Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford P","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, et al.. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017, 71:630-42. 10.1016\/j.eururo.2016.08.002","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Mohler JL","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ, et al.. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019, 17:479-505. 10.6004\/jnccn.2019.0023","journal-title":"J Natl Compr Canc Netw"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1126\/science.173.4001.1036","article-title":"Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones","volume":"173","author":"Schally AV","year":"1971","unstructured":"Schally AV, Arimura A, Kastin AJ, et al.. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science. 1971, 173:1036-8. 10.1126\/science.173.4001.1036","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(01)61831-7","article-title":"Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR)","volume":"161","author":"Ben-Josef E","year":"1999","unstructured":"Ben-Josef E, Yang SY, Ji TH, et al.. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol. 1999, 161:970-6.","journal-title":"J Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2165\/11208800-000000000-00000","article-title":"Degarelix: a guide to its use in advanced prostate cancer","volume":"28","author":"Lyseng-Williamson KA","year":"2010","unstructured":"Lyseng-Williamson KA. Degarelix: a guide to its use in advanced prostate cancer. Drugs Ther Perspect. 2010, 28:6-10. 10.2165\/11208800-000000000-00000","journal-title":"Drugs Ther Perspect"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2442","article-title":"Phase I trial of TAK-385 in hormone treatment-na\u00efve Japanese patients with nonmetastatic prostate cancer","volume":"8","author":"Suzuki H","year":"2019","unstructured":"Suzuki H, Uemura H, Mizokami A, et al.. Phase I trial of TAK-385 in hormone treatment-na\u00efve Japanese patients with nonmetastatic prostate cancer. Cancer Med. 2019, 8:5891-902. 10.1002\/cam4.2442","journal-title":"Cancer Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz L","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND, et al.. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008, 102:1531-8. 10.1111\/j.1464-410X.2008.08183.x","journal-title":"BJU Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2770","article-title":"Medical castration using the investigational oral GnRH antagonist TAK-385 (relugolix): phase 1 study in healthy males","volume":"100","author":"MacLean DB","year":"2015","unstructured":"MacLean DB, Shi H, Faessel HM, Saad F. Medical castration using the investigational oral GnRH antagonist TAK-385 (relugolix): phase 1 study in healthy males. J Clin Endocrinol Metab. 2015, 100:4579-87. 10.1210\/jc.2015-2770","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2018.1522372","article-title":"FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist","volume":"52","author":"Crawford ED","year":"2018","unstructured":"Crawford ED, Tombal B, Keane T, et al.. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018, 52:349-57. 10.1080\/21681805.2018.1522372","journal-title":"Scand J Urol"},{"key":"ref12","article-title":"The role of LHRH antagonists in the treatment of prostate cancer","volume":"23","author":"Crawford ED","year":"2009","unstructured":"Crawford ED, Hou AH. The role of LHRH antagonists in the treatment of prostate cancer. Oncology (Williston Park). 2009, 23:626-30.","journal-title":"Oncology (Williston Park)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.04.016","article-title":"Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?","volume":"33","author":"Vis AN","year":"2015","unstructured":"Vis AN, van der Sluis TM, Al-Itejawi HH, van Moorselaar RJ, Meuleman EJ. Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?. Urol Oncol. 2015, 33:7-15. 10.1016\/j.urolonc.2014.04.016","journal-title":"Urol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2017.06.008","article-title":"Risk of testosterone flare in the era of the saturation model: one more historical myth","volume":"5","author":"Krakowsky Y","year":"2019","unstructured":"Krakowsky Y, Morgentaler A. Risk of testosterone flare in the era of the saturation model: one more historical myth. Eur Urol Focus. 2019, 5:81-9. 10.1016\/j.euf.2017.06.008","journal-title":"Eur Urol Focus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2826.2009.01842.x","article-title":"Effects of gonadotrophin-releasing hormone outside the hypothalamic-pituitary-reproductive axis","volume":"21","author":"Skinner DC","year":"2009","unstructured":"Skinner DC, Albertson AJ, Navratil A, Smith A, Mignot M, Talbott H, Scanlan-Blake N. Effects of gonadotrophin-releasing hormone outside the hypothalamic-pituitary-reproductive axis. J Neuroendocrinol. 2009, 21:282-92. 10.1111\/j.1365-2826.2009.01842.x","journal-title":"J Neuroendocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.06.018","article-title":"GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model","volume":"32","author":"Hopmans SN","year":"2014","unstructured":"Hopmans SN, Duivenvoorden WC, Werstuck GH, Klotz L, Pinthus JH. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol. 2014, 32:1126-34. 10.1016\/j.urolonc.2014.06.018","journal-title":"Urol Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore ND","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, et al.. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020, 382:2187-96. 10.1056\/NEJMoa2004325","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.001","article-title":"The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant\/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: A randomised, open-label, parallel-group phase 2 trial","volume":"78","author":"Dearnaley DP","year":"2020","unstructured":"Dearnaley DP, Saltzstein DR, Sylvester JE, et al.. The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant\/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: A randomised, open-label, parallel-group phase 2 trial. Eur Urol. 2020, 78:184-92. 10.1016\/j.eururo.2020.03.001","journal-title":"Eur Urol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease","volume":"202","author":"Margel D","year":"2019","unstructured":"Margel D, Peer A, Ber Y, et al.. Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol. 2019, 202:1199-208. 10.1097\/JU.0000000000000384","journal-title":"J Urol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/1758835921998586","article-title":"Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer","volume":"13","author":"Saad F","year":"2021","unstructured":"Saad F, Shore ND. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Ther Adv Med Oncol. 2021, 13:1758835921998586. 10.1177\/1758835921998586","journal-title":"Ther Adv Med Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/322732-use-of-relugolix-for-the-prevention-of-impending-oliguria-and-progressive-renal-failure-in-a-suspected-case-of-prostate-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T08:37:29Z","timestamp":1737362249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/322732-use-of-relugolix-for-the-prevention-of-impending-oliguria-and-progressive-renal-failure-in-a-suspected-case-of-prostate-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.77692","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,20]]}}}